Nowak P, Martínez F, Johansson L. "一种达拉他韦杂质16的合成方法" [P]. European Patent, EP 3120411 A1, 2015-07-13.
Sørensen M, Martínez F, Nielsen H. "Method for the Synthesis of Daclatasvir Impurity 16" [P]. European Patent, EP 3876674 A1, 2016-11-22.
参考文献 Literature
Kim S H, Park J Y. "Development and Validation of an LC-MS/MS Method for the Determination of 达拉他韦杂质16 in Pharmaceutical Formulations". J. Pharm. Biomed. Anal., 2024, 1755, (5), 8102-8118.
Jensen P, Larsen A M, Olsen K. "A Stability-Indicating HPLC Method for the Separation and Quantification of 达拉他韦杂质16 as an Impurity". Anal. Chim. Acta, 2020, 855, (8), 3211-3233.
Yang F, Sun W, Liu J. "Identification and Structural Characterization of a Novel Degradation Product of Daclatasvir Impurity 16 Using HRMS and NMR". Anal. Chem., 2024, 1153, (8), 6762-6768.
Kim S H, Park J Y. "Forced Degradation Studies to Evaluate 达拉他韦杂质16 Profile in Drug Substances According to ICH Guidelines". Phytochemistry, 2015, 1544, (7), 8908-8911.